Evidence map›Paper›PMID 28447765›Full record

Trial reportMolecular medicine reports2017

Plasma microRNA-451 as a novel hemolytic marker for β0-thalassemia/HbE disease.

Kamonlak Leecharoenkiat, Yuka Tanaka, Yasuko Harada, Porntip Chaichompoo, Orawan Sarakul, Yasunobu Abe, Duncan Richard Smith, Suthat Fucharoen, Saovaros Svasti, Tsukuru Umemura

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. The Molecular Pathology of Non-Malignant Haematological Disease.British journal of biomedical science · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Post-transcriptional regulation of erythropoiesis.Blood science (Baltimore, Md.) · 2023
    Review
  10. Review
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. MicroRNAs and Long Non-coding RNAs in Genetic Diseases.Molecular diagnosis & therapy · 2019
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kamonlak LeecharoenkiatDepartment of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Yuka TanakaDivision of Medical Technology, Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan.
Yasuko HaradaDivision of Medical Technology, Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan.
Porntip ChaichompooDepartment of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Orawan SarakulDepartment of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Yasunobu AbeDepartment of Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan.
Duncan Richard SmithMolecular Pathology Laboratory, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom 73170, Thailand.
Suthat FucharoenThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom 73170, Thailand.
Saovaros SvastiThalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom 73170, Thailand.
Tsukuru UmemuraDivision of Medical Technology, Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan.
Kyushu University · JPMahidol University · THChulalongkorn University · THWalailak University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Southeast Asia, particularly in Thailand, β0-thalassemia/hemoglobin E (HbE) disease is a common hereditary hematological disease. It is associated with pathophysiological processes, such as the intramedullary destruction of immature erythroid cells and peripheral hemolysis of mature red blood cells. MicroRNA (miR) sequences, which are short non-coding RNA that regulate gene expression in a suppressive manner, serve a crucial role in human erythropoiesis. In the present study, the plasma levels of the erythroid-expressed miRNAs, miR‑451 and miR‑155, were analyzed in 23 patients with β0-thalassemia/HbE and 16 control subjects. Reverse transcription‑quantitative polymerase chain reaction analysis revealed significantly higher levels of plasma miR‑451 and miR‑155 in β0‑thalassemia/HbE patients when compared to the control subjects. Notably, among the β0‑thalassemia/HbE patients, a significant increase in miR‑451 levels was detected in severe cases when compared with mild cases. The levels of plasma miR‑451 correlated with reticulocyte and platelet counts. The results suggest that increased plasma miR‑451 levels may be associated with the degree of hemolysis and accelerated erythropoiesis in β0‑thalassemia/HbE patients. In conclusion, miR‑451 may represent a relevant biomarker for pathological erythropoiesis associated with β0-thalassemia/HbE.

Indexed as

ErythropoiesisHemolysisAdolescentAdultbeta-ThalassemiaBiomarkersFemaleHumansMaleMicroRNAsMiddle AgedBiomarkersMicroRNAsMIRN155 microRNA, humanMIRN451 microRNA, human

Identifiers

PMID28447765
PMCPMC5428399
OpenAlexW2600362526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.